Volume 73, Issue 4, Pages (April 2018)

Slides:



Advertisements
Similar presentations
Volume 56, Issue 5, Pages (November 2009)
Advertisements

Volume 72, Issue 1, Pages (July 2017)
Philipp Dahm, Ari D. Silverstein, Alon Z
Volume 70, Issue 3, Pages (September 2016)
Volume 59, Issue 2, Pages (February 2011)
The PSA Era is not Over for Prostate Cancer
Volume 68, Issue 2, Pages (August 2015)
Volume 68, Issue 6, Pages (December 2015)
Volume 53, Issue 4, Pages (April 2008)
Prostate Cancer: Highlights from 2006
Volume 74, Issue 2, Pages (August 2018)
Volume 73, Issue 6, Pages (June 2018)
Volume 73, Issue 6, Pages (June 2018)
Volume 51, Issue 4, Pages (April 2007)
Volume 73, Issue 1, Pages (January 2018)
Volume 70, Issue 4, Pages (October 2016)
Volume 60, Issue 6, Pages (December 2011)
Prostate Cancer Epidemic in Sight?
Volume 63, Issue 4, Pages (April 2013)
Volume 68, Issue 1, Pages (July 2015)
Volume 59, Issue 2, Pages (February 2011)
Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer  Sam Ladjevardi, Gabriel Sandblom,
Volume 67, Issue 2, Pages (February 2015)
Volume 68, Issue 5, Pages (November 2015)
Volume 72, Issue 6, Pages (December 2017)
Volume 53, Issue 4, Pages (April 2008)
Towards Early and More Specific Diagnosis of Prostate Cancer
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 62, Issue 1, Pages (July 2012)
Volume 68, Issue 3, Pages (September 2015)
Volume 184, Issue 4, Pages (October 2010)
Volume 71, Issue 5, Pages (May 2017)
Volume 71, Issue 6, Pages (June 2017)
Volume 63, Issue 4, Pages (April 2013)
Volume 53, Issue 4, Pages (April 2008)
Volume 73, Issue 2, Pages (February 2018)
Prostate Cancer Epidemic in Sight?
Thromboembolic Events Following Surgery for Prostate Cancer
The PSA Era is not Over for Prostate Cancer
Volume 68, Issue 6, Pages (December 2015)
Volume 53, Issue 4, Pages (April 2008)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 62, Issue 4, Pages (October 2012)
Volume 71, Issue 1, Pages (January 2017)
Volume 63, Issue 3, Pages (March 2013)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Volume 65, Issue 4, Pages (April 2014)
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Volume 50, Issue 5, Pages (November 2006)
Volume 72, Issue 4, Pages (October 2017)
Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study  Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,
Prostate Cancer Nomograms: An Update
Volume 71, Issue 3, Pages (March 2017)
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Volume 68, Issue 1, Pages (July 2015)
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 59, Issue 4, Pages (April 2011)
Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer  Felix Preisser, Michele Marchioni, Sebastiano.
Volume 72, Issue 1, Pages (July 2017)
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Thomas Steuber, Matthew Frank O'Brien, Hans Lilja  European Urology 
Volume 74, Issue 6, Pages (December 2018)
Volume 68, Issue 2, Pages (August 2015)
Volume 54, Issue 3, Pages (September 2008)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Volume 51, Issue 5, Pages (May 2007)
European Urology Oncology
Presentation transcript:

Volume 73, Issue 4, Pages 502-511 (April 2018) Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study  David Robinson, Hans Garmo, Ingela Franck Lissbrant, Anders Widmark, Andreas Pettersson, Adalsteinn Gunnlaugsson, Jan Adolfsson, Ola Bratt, Per Nilsson, Pär Stattin  European Urology  Volume 73, Issue 4, Pages 502-511 (April 2018) DOI: 10.1016/j.eururo.2017.11.039 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Flow chart of selection of study participants from Prostate Cancer data Base Sweden (PCBaSe) 3.0. Pca=prostate cancer; NPCR=National Prostate Cancer Register of Sweden; RP=radical prostatectomy; RT=radiotherapy. a Due to emigration (n=1), death from myocardial infarction at date of surgery (n=1), and date mismatch (n=11). b Later than 2 yr from the date of diagnosis. European Urology 2018 73, 502-511DOI: (10.1016/j.eururo.2017.11.039) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 Hazard ratios for prostate cancer (Pca) death shown for Cancer of the Prostate Risk Assessment (CAPRA) scores, with 95% confidence intervals. CAPRA is a scoring system from 0 to 10 based on age, PSA, Gleason score, clinical stage, and percent of biopsy cores involved with cancer. A high CAPRA score is associated with a poor prognosis [14]. Left truncation of data on January 1, 2011. PSA=prostate-specific antigen; RP=radical prostatectomy; RT=radiotherapy. a An assumption was made that the absolute 10-yr risk of Pca death for RT and RP is directly corresponding to the relative risk estimates. Then by considering the proportion of RT and the absolute 10-yr risk of Pca death for RT and RP combined in each CAPRA score category, an absolute 10-yr risk difference was calculated combining this with the relative risks. European Urology 2018 73, 502-511DOI: (10.1016/j.eururo.2017.11.039) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 3 Proportion prostate cancer (Pca) death among men treated with radiotherapy (RT) or radical prostatectomy (RP), divided into three time periods of treatment (solid dark green, green and light green lines). Proportion of Pca death during the full study period (dotted dark brown line) and with truncation on more recent dates (dotted light brown lines). European Urology 2018 73, 502-511DOI: (10.1016/j.eururo.2017.11.039) Copyright © 2017 European Association of Urology Terms and Conditions